Table 1 Characteristics of 122 patients with rheumatic diseases and 366 cancer-matched controls without RD
RA (n = 80) | SLE (n = 13) | SSc (n = 13) | DM/PM (n = 16) | All RD (n = 122) | Non-RD (n = 366) | |
|---|---|---|---|---|---|---|
Female, n (%) | 59 (73.8) | 13 (100.0) | 10 (76.9) | 6 (37.5) | 88 (72.1) | 264 (72.1) |
Age at RD dx, yrs, | 54.7 ± 12.8 | 42.4 ± 12.9 | 45.6 ± 16.1 | 58.2 ± 9.9 | 52.4 ± 13.5 | N/A |
Age at cancer dx, yrs, | 60.2 ± 11.3 | 52.2 ± 9.7 | 54.2 ± 13.9 | 59.7 ± 9.3 | 58.7 ± 11.5 | 58.6 ± 11.6 |
Follow-up duration, yrs | 14.4 ± 12.0 | 17.3 ± 10.2 | 10.7 ± 7.1 | 13.0 ± 11.2 | 12.8 ± 9.7 | 12.8 ± 9.7 |
Cancer type, n (%) | ||||||
Stomach | 18 (22.2) | 4 (30.8) | 2 (15.4) | 4 (25.0) | 28 (23.0) | 83 (22.7) |
Colon | 16 (20.0) | 3 (23.1) | 1 (7.7) | 3 (18.8) | 23 (18.9) | 69 (18.9) |
Lung | 28 (35.0) | 0 (0) | 10 (76.9) | 6 (37.5) | 44 (36.1) | 133 (36.3) |
Breast | 18 (22.5) | 6 (46.2) | 0 (0.0) | 3 (18.8) | 27 (22.1) | 81 (22.1) |
Interstitial lung disease, n (%) | 6 (7.5) | 1 (7.7) | 7 (53.8) | 3 (18.8) | 17 (13.9) | 3 (0.8) |
Treatment of RD, n (%) | ||||||
Methotrexate | 53 (66.3) | 1 (7.7) | 0 (0) | 5 (31.3) | 59 (48.4) | N/A |
Other DMARDs | 57 (71.3) | 6 (46.2) | 2 (15.4) | 6 (37.5) | 71 (58.2) | N/A |
Corticosteroids | 48 (60.0) | 7 (58.3) | 4 (30.8) | 13 (81.3) | 72 (59.0) | N/A |
TNF inhibitors | 4 (5.0) | 0 (0) | 0 (0) | 0 (0) | 4 (3.3) | N/A |
Othersa | 5 (6.3) | 4 (30.8) | 2 (15.4) | 4 (25.0) | 15(12.3) | N/A |